FDA approvals – Sep 2020
In September, the FDA approved 2 new medications in the oncology & hematology category.
- Pralsetinib was approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
- Azacitidine tablets were approved for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
